Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1 [Retraction]
Yang J, Li B, Zhao S, Du H, Du Y. Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1. Onco Targets Ther. 2020;13:6709–6720.
At the request of the author, the Editor and Publisher of OncoTargets and Therapy wish to retract the published paper.
Following a review of their paper the authors have determined that due to a lack of data they can no longer confirm this study showed an anti-cancer role of exosome miR-638 in hepatocellular carcinoma (HCC) by inhibiting angiogenesis. The authors also confirmed they could no longer locate the original data for this study. In the interests of scientific integrity, the authors have agreed it best to retract the published article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]